Author Archives: Joana Carvalho

Despite having lower respiratory muscle strength, people with pulmonary arterial hypertension (PAH) can still use dry powder inhalers that require breath-actuated force to effectively deliver inhaled therapies, a study has found. The study, “Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial…

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by Insmed for treating pulmonary arterial hypertension (PAH) — was safe and well-tolerated in healthy volunteers. Results also showed…

The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ injectable formulation of treprostinil, a generic version of Remodulin, to treat patients with pulmonary arterial hypertension (PAH), the company announced. Like the branded product, this generic version of United Therapeutics’ treprostinil will be available in multiple-dose vials…

United Therapeutics is planning to ask the U.S. Food and Drug Administration (FDA) for an accelerated review of Tyvaso DPI, an investigational therapy-inhaler device treatment for two forms of pulmonary hypertension, in an approval request it expects to file by midyear. The request, in the form of a new drug…

The Pulmonary Hypertension Association U.K. (PHA UK), a charity organization dedicated to supporting those with pulmonary hypertension (PH), is urging adults with PH to participate in a research study assessing the usefulness of a self-help program to manage anxiety. By participating in the study patients will have…

The U.S. Food and Drug Administration (FDA) determined that additional data is required to support the potential approval of LIQ861, Liquidia Technologies’ investigational inhaled formulation of treprostinil, for the treatment of pulmonary arterial hypertension (PAH). The U.S. agency issued a complete response…

Liquidia Technologies, the developer of an inhaled formulation of treprostinil (LIQ861) for the treatment of pulmonary arterial hypertension (PAH), has completed its acquisition of RareGen, the marketer of generic treprostinil injections. The…

Tenax Therapeutics  has acquired developmental and commercial rights for North America to an oral formulation of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax plans to open a Phase 3 safety and efficacy trial of…

An imbalance in the composition of bacteria living in the gut, a phenomenon known as dysbiosis, may play a key role in the onset and progression of pulmonary arterial hypertension (PAH), a study in animals suggests. The study, “Gut microbiota modification suppresses the development of…

Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use as a template to make proteins; specifically, mRNAs carry the genetic code from DNA to the protein-making…

Despite current targeted therapies, premature babies with bronchopulmonary dysplasia or BPD — a disease in which the lungs become irritated and fail to develop properly, causing breathing difficulties — associated with pulmonary hypertension (PH) continue to have high mortality rates, a study found. Nevertheless, infants who live past…

Robot-assisted pulmonary artery denervation (PADN) — a minimally invasive surgical procedure that destroys some of the nerves innervating the pulmonary artery to reduce blood pressure — can lower heart strain and improve exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH). That finding was reported in…